Clinical Trials Sponsored by PENTA Foundation

Total 15920 results

PENTA Foundation

Completed

Early Anti-Retroviral Treatment in HIV- Infected Children

HIV Infections

South Africa, Mali, Mozambique
PENTA Foundation

Completed

PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months (PENTA15)

HIV Infection

France, Germany, Italy, Spain, United Kingdom
PENTA Foundation

Completed

Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children (PENTA 13)

HIV Infection

United Kingdom
PENTA Foundation
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis (NeoMero-2)

Meningitis

United Kingdom
PENTA Foundation
Chiesi Farmaceutici S.p.A.

Completed

Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis (NeoMero-1)

Sepsis

Italy
Bristol-Myers Squibb
PENTA Foundation

Completed

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

HIV Infection

Romania, Belgium, Germany, Italy, Spain, Switzerland, United Kingdom
Fondazione Penta UK
UCL Great Ormond Street Institute of Child Health

Recruiting

Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)

HIV Infections

Spain, Switzerland, United Kingdom, Belgium, Italy, Romania, Russian Federation
NEAT ID Foundation
PENTA Foundation; European Commission; VERDI Consortium

Recruiting

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV (MASH 1)

Monkeypox | HIV Coinfection

Spain, France, Poland, United Kingdom
PENTA Foundation
Medical Research Council; ANRS, Emerging Infectious Diseases

Completed

KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) (KONCERT)

Antiretroviral Therapy in HIV-1 Infected Children

Netherlands, Germany, United Kingdom, Ireland, Thailand
PENTA Foundation
Medical Research Council; ANRS, Emerging Infectious Diseases

Unknown

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection (BREATHER)

HIV

United Kingdom, Uganda, Ireland, United States, France, Germany, Thailand, Ukraine
Genta Incorporated

Unknown

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Breast Neoplasm

United States
Genta Incorporated

Unknown

Study of Tesetaxel in Japanese Patients With Solid Tumors

Advanced Solid Tumors

Japan
Genta Incorporated

Completed

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

Normal Renal Function | Mildly Impaired Renal Function | Moderately Impaired Renal Function

United States
Genta Incorporated

Unknown

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Melanoma

United States
Genta Incorporated

Completed

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Genta Incorporated

Completed

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma (AGENDA)

Melanoma

United States, France, United Kingdom, Spain, Switzerland, Australia, Canada, Germany, Poland, Italy, Austria, Czech Republic
Genta Incorporated

Withdrawn

This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Lymphocytic Leukemia
Genta Incorporated

Completed

A Phase I Study of G3139 Subcutaneous in Solid Tumors

Tumors

United States
PENTA Foundation
ViiV Healthcare; Hospital Universitario 12 de Octubre; Cromsource; PHPT Foundation

Recruiting

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

HIV Infections With Multi Drug Resistant Virus

United States, South Africa, Mexico, Spain
PENTA Foundation
Universiteit Antwerpen; St George's, University of London; BioMérieux

Completed

Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms (ADEQUATE)

Community-acquired Acute Lower Respiratory Infection

Switzerland
Pentax Medical

Completed

Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

Barrett's Esophagus

Netherlands
Pentax Medical

Completed

Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium

Esophageal Cancer | Barrett's Esophagus

United States, Netherlands
Pentax Medical

Completed

Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

Barrett's Esophagus

United States, Netherlands
Pentax Medical

Completed

Evaluation of Safety and Dose Response Using C2 CryoBalloon™ Swipe Ablation System for Barrett's Esophagus

Barrett Esophagus

Netherlands
Pentax Medical

Completed

Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium

Esophageal Cancer

United States
Pinta Biotherapeutics

Completed

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

End Stage Renal Disease | Kidney Disease | Protein Energy Wasting

United States
Genta Incorporated

Unknown

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer (TESEGAST)

Gastric Carcinoma

Taiwan, United States, Germany
Genta Incorporated

Unknown

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Prostate Cancer

United States
Genta Incorporated

Unknown

Tesetaxel for Previously Treated Patients With Bladder Cancer

Carcinoma, Transitional Cell

United States, Italy
Genta Incorporated

Unknown

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Non-resectable Breast Cancer

United States
Genta Incorporated

Terminated

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Advanced Melanoma and Normal or Impaired | Hepatic Function
Genta Incorporated

Completed

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Low-Grade Lymphoma | Intermediate-Grade Lymphoma

United States
Pentax Medical

Not yet recruiting

C2 Esophageal Squamous Epithelium Dysplasia

Esophageal Squamous Epithelium Dysplasia

China
Pentax Medical

Enrolling by invitation

C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.

Barrett Esophagus

Netherlands
Pentax Medical

Completed

Clinical Study to Evaluate CryoBalloon™ Ablation System in Patients Undergoing Esophagectomy

Esophageal Cancer

Netherlands
Pentax Medical

Active, not recruiting

Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System (ColdPlayIII)

Barrett Esophagus

United States
Pentax Medical

Completed

Coldplay Cryoablation of Dysplastic Squamous Tissue in Patients With Esophageal Squamous Cell Dysplasia

Esophageal Squamous Cell Dysplasia

China
Genta Incorporated

Unknown

A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors

Solid Tumor

United States
Genta Incorporated

Completed

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

Solid Tumors

United States
Genta Incorporated

Completed

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

Solid Tumors

United States
Genta Incorporated

Unknown

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction

United States, Korea, Republic of
Genta Incorporated

Unknown

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Gastric Carcinoma

Korea, Republic of
Genta Incorporated

Completed

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

Advanced Melanoma
Genta Incorporated

Unknown

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Melanoma

United States
Genta Incorporated

Completed

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | CLL

United States
Kenta Biotech Ltd

Completed

Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa

Pneumonia | Ventilator Associated Pneumonia

Switzerland
New Penta SRL
IRCCS San Raffaele

Unknown

Th Effect of Ketogenic Metabolic Nutritional Pattern on High-frequency Episodic Migraine (EMIKETO) (EMIKETO)

Brain Diseases | Overweight | Migraine | Weight Loss | Ketogenic Dieting

Italy
Penza State University

Recruiting

Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19 (CONTRAST-3)

Covid19 | STEMI | NSTEMI

Russian Federation
Penza State University

Recruiting

Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI (CONTRAST-2)

Quality of Life | Arterial Stiffness | Myocardial Infarction, Acute | Myocardial Strain

Russian Federation
Penza State University

Completed

Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI (CONTRAST)

Myocardial Infarction

Russian Federation

3

Subscribe